MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
Yao-Sheng WangYi-Gang Li

Abstract

MicroRNAs play regulatory role in cardiovascular disease. MicroRNA-223 (miR-223) was found to be expressed abundantly in myocardium. TNNI3K, a novel cardiac troponin I (cTnI)-interacting and cardiac hypertrophy related kinase, is computationally predicted as a potential target of miR-223. This study was designed to investigate the cellular and molecular effects of miR-223 on cardiomyoctye hypertrophy, focusing on the role of TNNI3K. Neonatal rat cardiomyocytes (CMs) were cultured, and CMs hypertrophy was induced by endothelin-1 (ET-1). In vivo cardiac hypertrophy was induced by transverse aorta constriction (TAC) in rats. Expression of miR-223 in CMs and myocardium was detected by real-time PCR (RT-PCR). MiR-223 and TNNI3K were overexpressed in CMs via chemically modifed sense RNA (miR-223 mimic) transfection or recombinant adenovirus infection, respectively. Cell size was measured by surface area calculation using fluorescence microscopy after anti-α-actinin staining. Expression of hypertrophy-related genes was detected by RT-PCR. The protein expression of TNNI3K and cTnI was determined by Western blots. Luciferase assay was employed to confirm the direct binding of miR-223 to the 3'UTR of TNNI3K mRNA. Intracellular calcium wa...Continue Reading

Citations

Mar 26, 2016·Trends in Cardiovascular Medicine·Saheli SamantaJohnson Rajasingh
Jul 8, 2015·Nature Reviews. Cardiology·David D McManus, Jane E Freedman
Jun 13, 2015·Journal of the American College of Cardiology·Jason C Kovacic
May 24, 2016·International Journal of Molecular Sciences·Juan WangYei-Tsung Chen
Jul 4, 2016·International Journal of Cardiology·Gang DuJinhua Wang
Nov 3, 2017·BioMed Research International·Chao ChenPeifeng Li
Mar 6, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia CavallariVincenzo Cantaluppi
Sep 2, 2020·American Journal of Hypertension·Fu-Han GongWen-Lin Cheng
Feb 18, 2017·BioMed Research International·Ximin FanDachun Xu
Sep 2, 2018·Journal of Cardiovascular Translational Research·Yongqin LiYihua Bei
Sep 26, 2019·Cardiovascular Research·Tingsen Benson LimRoger Sik-Yin Foo
Oct 31, 2018·Journal of Human Hypertension·Maria MarketouFragiskos Parthenakis
Jan 4, 2021·Molecular and Cellular Biochemistry·Samira Tabaei, Seyyedeh Samaneh Tabaee
Feb 9, 2021·Frontiers in Cardiovascular Medicine·Meng-Wan ZhangJian-Guang Yu
Mar 28, 2021·Journal of Physiology and Biochemistry·Yuejia DingJunping Zhang
May 28, 2019·Clinical Biochemistry·Torkia Lalem, Yvan Devaux
Jul 3, 2021·International Journal of Molecular Sciences·Caroline PhamElisabeth M Lodder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.